Diego J Maselli, MD, FCCP
Associate Professor of Medicine
Division of Pulmonary Diseases & Critical Care
University of Texas Health Science Center at San Antonio
Director, Severe Asthma Program
University Health System
San Antonio, TX
Nicola A Hanania, MD, MS, FCCP
Associate Professor of Medicine
Section of Pulmonary and Critical Care Medicine
Director, Airways Clinical Research Center
Baylor College of Medicine
This enduring program consists of presentations from expert faculty and simulation challenge animations that will explain immune dysfunction and the pathogenesis of moderate-to-severe asthma, currently available and emerging targeted therapies used for asthma, and the usefulness and application of guidelines and biomarkers to guide treatment selection for this disease.
This activity is designed to meet the needs of allergists, immunologists, and other healthcare providers involved in the care of patients with moderate-to-severe asthma.
Upon the completion of this program, learners should be able to:
- Utilize knowledge of the type 2 inflammatory pathway to select therapies that target the underlying chronic inflammation associated with severe asthma and other commonly comorbid conditions
- Assess disease severity and identify patients who require step-up therapy to manage symptoms, minimize systemic steroid use and reduce emergency room visits
- Design evidence-based treatment plans for pediatric and adult patients with moderate-to-severe asthma that include patient-specific factors, such as comorbidities, quality of life, and treatment responses
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: Education regarding the management of moderate-to-severe asthma leads to safe practices, quality care, and continued professional and personal development for nurses.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIP
Diego J Maselli, MD reports that he has received consulting fees from Amgen, AstraZeneca, Genentech, GlaxoSmithKline, and Sanofi Regeneron. He serves on the speakers’ bureau for AstraZeneca, GlaxoSmithKline, and Sanofi Regeneron.
Nicola A Hanania, MD reports that he has received consulting fees from Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi, and Teva. He serves on the speakers’ bureau for AstraZeneca, Mylan, and Sanofi. He receives funding for contracted research from AstraZenca, Boehringer Ingelheim, Genentech, Gossamer Bio, GSK, Novartis, Sanofi, and Teva.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Chris Drury MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Ashley Whitehurst, Program Manager for Med Learning Group, has nothing to disclose.
Natalie Smith, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the activity.
- Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at email@example.com
RELEASE DATE: December 07, 2021
EXPIRATION DATE: December 07, 2022
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.